A District Court judge issued a nationwide preliminary injunction against the administration’s plan to cap so-called indirect costs associated with NIH grants — a policy with broad implications for the U.S. drug industry.
A District Court judge issued a nationwide preliminary injunction against the administration’s plan to cap so-called indirect costs associated with NIH grants — a policy with broad implications for the U.S. drug industry.
